Guidelines for Dia­gnosis and Treatment of Lower Urinary Tract Symp­toms in Patients with Multiple Sclerosis in the Czech Republic –  Interdisciplinary Expert Consensus Us­ing DELPHI Methodology

2017 ◽  
Vol 80/113 (2) ◽  
pp. 233-236
Author(s):  
Jan Krhut ◽  
Olga Zapletalová ◽  
Roman Zachoval ◽  
Eva Meluzínová ◽  
Libor Zámečník ◽  
...  
2019 ◽  
Author(s):  
Fatemeh Nazari ◽  
Vahid Shaygannejad ◽  
Mehrdad Mohammadi Sichani ◽  
Marjan Mansourian Gharaagozlou ◽  
Valiollah Hajhashemi

Abstract Background Most patients with multiple sclerosis (MS) suffer from bladder dysfunction during the course of the disease. This study was conducted to examine the prevalence of these complications among patients with MS. Methods This cross-sectional study was performed on 603 patients with MS who referred to the neurology clinics of Kashani and Alzahra Hospitals affiliated to Isfahan University of Medical Sciences, Isfahan, Iran. The sampling was performed by multi-stage random cluster sampling method and the informed consent form was filled in by the subjects. Then, all the data were collected through interviews using the Lower Urinary Tract Symptom Score (LUTSS) developed in accordance with the definitions presented by the International Continence Society (ICS) and the International Prostate Symptom Score (I-PSS). The data were analyzed using descriptive and inferential statistical tests in SPSS and the significance level was considered to be less than 0.050. Results The prevalence rate of lower urinary tract symptoms (LUTS) was 87.6% among all the subjects, with a similar rate among women (88.0%) and men (86.0%). There was a significant difference between the two groups of men and women in terms of the prevalence of stress urinary incontinence (SUI), intermittent urine flow, hesitancy, straining, and dribbling (P < 0.050). There was no significant difference between the two groups of women and men in terms of the prevalence of other symptoms (P > 0.050). Moreover, there was a significant difference between the degree of LUTS with age, marital status, education, duration of illness, clinical course, and disability (P < 0.05). Conclusions A high prevalence of LUTS was found among patients with MS, with similar rates in men and women, and the nature of the urinary complaints and LUTS was different among men and women with MS. Therefore, it is recommended that the health system take necessary measures regarding timely detection and treatment of LUTS among these patients in order to prevent secondary outcomes and improve the quality of life (QOL) of patients with MS.


Urology ◽  
1992 ◽  
Vol 39 (1) ◽  
pp. 67-70 ◽  
Author(s):  
Michael E. Mayo ◽  
Michael P. Chetner

1991 ◽  
Vol 145 (6) ◽  
pp. 1219-1224 ◽  
Author(s):  
Bart L.H. Bemelmans ◽  
Otto R. Hommes ◽  
Philip E.V. Van Kerrebroeck ◽  
Wim. A.J.G. Lemmens ◽  
Wim. H. Doesburg ◽  
...  

2017 ◽  
Vol 11 (3-4) ◽  
pp. 110 ◽  
Author(s):  
Shachar Moshe Aharony ◽  
Ornella Lam ◽  
Jacques Corcos

Multiple sclerosis (MS) is a unique neurological disease with a broad spectrum of clinical presentations that are time- and disease course-related. Lower urinary tract symptoms (LUTS) are highly prevalent in this patient population, with approximately 90% showing some degree of voiding dysfunction and/or incontinence 6–8 years after the initial MS diagnosis. Major therapeutic goals include quality of life improvement and the avoidance of urological complications Owing to the wide divergence of clinical symptoms and disease course, evaluation and treatment differ between patients. Treatment must be customized for each patient based on disease phase, patient independence, manual dexterity, social support, and other medical- or MS-related issues. Ablative or irreversible therapies are indicated only when the disease course is stable. In most cases of “safe” bladder, behavioural treatment is considered first-line defense. Antimuscarinic drugs, alone or in combination with intermittent self-catheterization, are currently the mainstay of conservative treatment, and several other medications may help in specific disease conditions. Second-line treatment includes botulinum toxin A injection, neuromodulation, indwelling catheters, and surgery in well-selected cases.


2016 ◽  
Vol 36 (4) ◽  
pp. 1208-1213 ◽  
Author(s):  
Benjamin M. Brucker ◽  
Victor W. Nitti ◽  
Sidhartha Kalra ◽  
Joseph Herbert ◽  
Areeba Sadiq ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document